<DOC>
	<DOCNO>NCT01679652</DOCNO>
	<brief_summary>Investigators want investigate follow hypothesis : 1 . Nebivolol increase nitric oxide activity systemic circulation kidney 2 . The increased activity nitric oxide nebivolol treatment demonstrate inhibition NO synthesis L-NMMA . We expect increased response blood pressure sodium excretion expect nebivolol treatment compare placebo .</brief_summary>
	<brief_title>The Effects Nebivolol NO-system Patients With Essential Hypertension</brief_title>
	<detailed_description>Beta-blockers longer recommend first line treatment essential hypertension . Evidence mainly base clinical trail non-vasodilating beta-blockers atenolol propanolol point towards beta-blockers increase risk stroke compare ACE-inhibitors , calcium channel blocker thiazide . However , Nebivolol third generation beta-blocker vasodilating property . Nebivolol decrease peripheral blood pressure extend beta-blockers contrast atenolol nebivolol also reduce central blood pressure . Furthermore nebivolol increase nitric oxide ( NO ) availability forearm vessel , maybe activation beta-3 receptor . The nitric oxide system play central role renal sodium water handle regulation vascular tone blood pressure . It investigate nebivolol change NO availability kidney . Investigators want investigate follow hypothesis : 1 . Nebivolol increase nitric oxide activity systemic circulation kidney 2 . The increased activity nitric oxide nebivolol treatment demonstrate inhibition NO synthesis L-NMMA . Investigators expect increase response blood pressure sodium excretion expect nebivolol treatment compare placebo . Purpose The purpose study investigate effect nebivolol renal handling sodium water ( Glomerular filtration rate , urine production , free water clearance , excretion protein epithelial sodium channel ( u-ENaCαβγ ) aquaporin channel ( u-AQP2 ) sodium potassium excretion ) , plasma concentration vasoactive hormone ( renin , angiotensin II , aldosterone , vasopressin , atrial natriuretic peptide , brain natriuretic peptide endothelin ) , central blood pressure , pulse wave velocity ( PWV ) augmentation index , basal condition inhibition nitric oxide synthesis patient essential hypertension . Design 25 patient essential hypertension recruit randomise , cross , placebo-controlled , double blind study two treatment period ( nebivolol/placebo ) . Each subject attend two examination day . Four day prior examination day morning examination day subject give either nebivolol 5 mg pr . day placebo . During treatment period subject give standardized diet . On examination day subject give L-NMMA , nitric oxide synthase inhibitor , renal function , central hemodynamic vasoactive hormone evaluate basal condition inhibition nitric oxide synthesis . Perspectives This study expect contribute increase knowledge mechanism involve development progression cardiovascular disease . Beta-blockers recommend first line treatment essential hypertension result study may influence clinical treatment essential hypertension future .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Increased blood pressure ( 135 mmHg systolic 85 mmHg diastolic day time 24 hour blood pressure measurement take 5 10 mg amlodipine Men woman age 40 70 year informed consent diabetes mellitus glomerular filtration rate &lt; 30 ml/min albuminuria &gt; 1,5 g/l renogram suggest secondary hypertension clinical sign pheochromocytoma increase pmetanephrines clinical important sign og heart , lung , liver , thyroid neoplastic disease clinical important deviation routine blood sample ECG drug alcohol abuse pregnancy nursery intolerance nebivolol blood donation month first examination day inacceptable increase blood pressure durin LNMMA infusion ( 200/120 ) inacceptable side effect amlodipine blood pressure increase 170/105 high dose amlodipine ( 10 mg )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Nitric oxide</keyword>
	<keyword>Nebivolol</keyword>
	<keyword>Fractional excretion sodium</keyword>
</DOC>